Laboratory for Control, Learning, and Systems Biology

oncolytic therapy

2017
  1. S. Barish, M.F. Ochs, E.D. Sontag, J.L. Gevertz, "Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy", Proc Natl Acad Sci USA, vol. 114, pp. E6277-E6286, 2017. wwwdoipdf
    Abstract

    This paper proposes a technique that combines experimental data, mathematical modeling, and statistical analyses for identifying optimal treatment protocols that are robust with respect to individual variability. Experimental data from a small sample population is amplified using bootstrapping to obtain a large number of virtual populations that statistically match the expected heterogeneity. Alternative therapies chosen from among a set of clinically-realizable protocols are then compared and scored according to coverage. As proof of concept, the method is used to evaluate a treatment with oncolytic viruses and dendritic cell vaccines in a mouse model of melanoma. The analysis shows that while every scheduling variant of an experimentally-utilized treatment protocol is fragile (non-robust), there is an alternative region of dosing space (lower oncolytic virus dose, higher dendritic cell dose) for which a robust optimal protocol exists.